Althea Dimaculangan
Family · McDonough, GANPI 1609255066
Payments from drug & device makers
Across 362 payments — averaging $17.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$1K
- Bayer$929
- Lilly USA, LLC$622
- Shield Therapeutics Inc$497
- GSK$391
- plus $2K from 18 others
What the payments were for
- Food & beverage$6,44199%
- Education$441%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 79 | $1,132 |
| Novo Nordisk | 56 | $1,001 |
| Bayer | 27 | $929 |
| Lilly USA, LLC | 41 | $622 |
| Shield Therapeutics Inc | 23 | $497 |
| GSK | 14 | $391 |
| Amgen(2 entities) | 16 | $294 |
| Pfizer | 18 | $270 |
| Kowa Pharmaceuticals America, Inc. | 26 | $228 |
| AstraZeneca | 5 | $182 |
| Boehringer Ingelheim | 10 | $181 |
| Biohaven Pharmaceutical Holding Company Ltd. | 15 | $177 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $114 |
| Amarin Pharma, Inc. | 6 | $101 |
| Biohaven Pharmaceuticals, Inc. | 5 | $93 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $71 |
| Corcept Therapeutics | 2 | $43 |
| Phathom Pharmaceuticals, Inc. | 2 | $33 |
| Dexcom, Inc. | 2 | $31 |
| Astellas Pharma US Inc | 1 | $26 |
| Phadia US Inc. | 1 | $22 |
| Exact Sciences | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$500
- TRELEGY ELLIPTA$125
- AIRSUPRA$125
- VRAYLAR$121
- Saxenda$105
How this compares
$6,485 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 173 | $244,769 |
| JardianceEmpagliflozin | 158 | $215,097 |
| OzempicSemaglutide | 70 | $107,917 |
| VascepaIcosapent Ethyl | 119 | $107,470 |
| KerendiaFinerenone | 55 | $89,669 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 65 | $55,848 |
| RybelsusSemaglutide | 24 | $55,686 |
| LinzessLinaclotide | 42 | $47,823 |
| EliquisApixaban | 31 | $38,077 |
| Repatha SureclickEvolocumab | 22 | $25,160 |
| Tresiba Flextouch U-200Insulin Degludec | 30 | $20,786 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $19,698 |
| VraylarCariprazine Hcl | 14 | $19,354 |
| TrulicityDulaglutide | 13 | $19,319 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 31 | $16,660 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $622 | $264,087186 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat | $181 | $238,414202 claims |
| Novo NordiskOzempic, Rybelsus | $1,001 | $163,60394 claims |
| BayerKerendia | $929 | $89,66955 claims |
| AbbVieLinzess, Vraylar, Restasis | $1,132 | $75,52067 claims |
| GSKTrelegy Ellipta | $391 | $55,84865 claims |
| PfizerEliquis | $270 | $38,07731 claims |
| Astellas Pharma US IncMyrbetriq | $26 | $15,13815 claims |
| AstraZenecaBreztri Aerosphere | $182 | $8,00411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.
Other family in McDonough
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
- Jessica FeehanCanton$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.